Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.

医学 达拉图穆马 内科学 耐火材料(行星科学) CD38 肿瘤科 耐受性 胃肠病学 蛋白酶体抑制剂 来那度胺 多发性骨髓瘤 不利影响 川地34 物理 干细胞 天体生物学 生物 遗传学
作者
Bhagirathbhai Dholaria,Katja Weisel,María‐Victoria Mateos,Hartmut Goldschmidt,Thomas G. Martin,Daniel Morillo,Donna Reece,Paula Rodríguez‐Otero,Manisha Bhutani,Anita D’Souza,Albert Oriol,Laura Rosiñol,Nizar J. Bahlis,Kalpana Bakshi,Lijuan Kang,Lien Vandenberk,Marie-Anne Damiette Smit,Ralph Wäsch,Niels W.C.J. van de Donk,Ajai Chari
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (16_suppl): 8003-8003 被引量:43
标识
DOI:10.1200/jco.2023.41.16_suppl.8003
摘要

8003 Background: Tal is a T-cell redirecting bispecific antibody (BsAb) targeting G protein–coupled receptor family C group 5 member D. Dara is an anti-CD38 mAb with direct on-tumor and immunomodulatory actions. Combining immunomodulatory effects of tal + dara may lead to synergistic efficacy. Initial TRIMM-2 (NCT04108195) results showed that SC tal RP2Ds, 0.4 mg/kg QW or 0.8 mg/kg Q2W, + SC dara had promising efficacy and increased CD38+/CD8+ T cells and proinflammatory cytokines. We report updated results with additional pts and longer follow-up. Methods: Pts had MM, ≥3 prior lines of therapy (LOT; including a proteasome inhibitor [PI] and immunomodulatory drug [IMiD]) or were double refractory to a PI and IMiD, and had not received anti-CD38 therapy in ≤90 d. Pts received tal RP2Ds with step-up dosing + dara 1800 mg per approved schedule. AEs were graded per CTCAE v5.0; cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) were graded per ASTCT guidelines. Responses were assessed per IMWG criteria. Results: As of Dec 12, 2022 (N = 65), median follow-up was 11.5 mo (range 1.0–27.3). Median age was 63 y (range 37–81); 18% of pts had high-risk cytogenetics; 25% had extramedullary plasmacytomas. Median prior LOT was 5 (range 2–16): 63% penta-drug exposed; 58% triple-class refractory. Prior treatments included anti-CD38 (88% [77% refractory]), anti-BCMA (54% [38%]), BsAb (25% [25%]), and anti-BCMA CAR-T (17% [2%]) therapy. All pts had ≥1 AE (grade [Gr] 3/4 78%), most commonly CRS (78%; all Gr 1/2), dysgeusia (75%), dry mouth (55%), anemia (52%), fatigue (45%), and skin exfoliation (45%). CRS had a median time to onset of 1 d after the most recent dose with median duration of 2 d. 63% of pts had infections (Gr 3/4 22%; Gr 5 3% [n = 2 pneumonia, possibly related to tal + dara]). 38% of pts had neutropenia (Gr 3/4 26%). 85% had postbaseline IgG < 500 mg/dL; of these, 32% received IVIg. ICANS occurred in 3 pts (5%; all Gr 1/2 and resolved in 1–2 d). ORR was 78% (66% ≥VGPR; 45% ≥CR) across RP2Ds (100% in anti-CD38 naïve pts), and responses deepened over time. In pts exposed/refractory to prior therapy, ORRs were 75%/76% for anti-CD38, 74%/64% for anti-BCMA, and 75%/75% for BsAb. Median time to first response was 1 mo (range 0.9–8.3); at 12 mo, 86% of responders (89% of pts with ≥CR) still had responses. At data cutoff, 84% of responders remain on therapy (83%/82% anti-CD38 exposed/refractory). mPFS was 19.4 mo; 12-mo PFS and OS rates were 76% and 93%, respectively. Conclusions: Steroid-sparing tal + dara showed deep and durable responses with promising mPFS in heavily pretreated pts with RRMM, including pts refractory to anti-CD38/BCMA and T-cell redirecting therapy, suggesting combined immunomodulatory actions can yield robust responses in pts with refractory disease. The safety profile was clinically manageable; no new signals were identified with longer follow-up.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wyr发布了新的文献求助10
刚刚
jeatit完成签到,获得积分10
刚刚
刚刚
1秒前
she996发布了新的文献求助30
1秒前
1秒前
谢ber发布了新的文献求助10
1秒前
lululiya完成签到,获得积分10
1秒前
所所的应助被白晨采纳,获得10
1秒前
于是乎发布了新的文献求助10
1秒前
Liuleer关注了科研通微信公众号
1秒前
1秒前
123发布了新的文献求助10
2秒前
李爱国的应助被LS采纳,获得10
2秒前
king发布了新的文献求助10
2秒前
深情安青的应助被orange_hua采纳,获得10
2秒前
CM发布了新的文献求助10
2秒前
Link完成签到,获得积分10
2秒前
Sea完成签到,获得积分10
2秒前
传奇3的应助被英俊糖豆采纳,获得10
2秒前
CheeseD发布了新的文献求助10
4秒前
姜博超完成签到,获得积分10
4秒前
本本完成签到,获得积分10
4秒前
烟花的应助被kevin采纳,获得20
4秒前
尊敬访云发布了新的文献求助10
4秒前
5秒前
香蕉觅云的应助被飘逸雨竹采纳,获得10
5秒前
光亮澜完成签到,获得积分10
5秒前
5秒前
5秒前
无花果的应助被白晨采纳,获得10
5秒前
悬停之翼发布了新的文献求助10
5秒前
秋风的应助被米mi采纳,获得10
5秒前
6秒前
初初初啊发布了新的文献求助10
6秒前
6秒前
拟晓汁发布了新的文献求助10
6秒前
海山了完成签到,获得积分10
6秒前
蒋畅发布了新的文献求助10
6秒前
缥缈听白的应助被明理飞风采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170142
求助须知:如何正确求助?哪些是违规求助? 9563136
关于积分的说明 21768635
捐赠科研通 7761603
什么是DOI,文献DOI怎么找? 3430600
关于科研通互助平台的介绍 2554420
邀请新用户注册赠送积分活动 2475330